Bentley Pharmaceuticals' Pricing in Spain Pressured by New Regulation from the Ministry of Health.

EXETER, N.H. -- Bentley Pharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceutical company, today reported that, on December 30, 2006, the Spanish Ministry of Health adopted a regulation that lowers the amount the government will reimburse for several pharmaceutical products sold in Spain. The regulation takes effect on March 1, 2007.

The new regulation affects a major portion of the Company's pharmaceutical product sales in Spain. If the regulation had been in effect during 2006, the Company's consolidated revenue would have been reduced by approximately 10 to 12 percent based on 2006 projected product mix and volumes.

"We experienced a similar event in 2003 and took effective steps to mitigate the impact on our overall results," said John A. Sedor, President. "In response to this latest regulation, we are currently considering several similar measures, including new product launches, increased unit sales and further geographic diversification outside of Spain, as well as reductions in material and production costs."

Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on advanced drug delivery technologies and generic pharmaceutical products. Bentley's proprietary drug delivery technologies enhance the absorption of pharmaceutical compounds across various membranes. Bentley manufactures and markets a growing portfolio of generic and branded generic pharmaceuticals in Europe for the treatment of cardiovascular, gastrointestinal, infectious and neurological diseases through its subsidiaries -- Laboratorios Belmac, Laboratorios Davur, Laboratorios Rimafar and Bentley Pharmaceuticals Ireland. Bentley also manufactures and markets active pharmaceutical ingredients through its subsidiary, Bentley API.

Additional information regarding Bentley Pharmaceuticals may be obtained through Bentley's web site at www.bentleypharm.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward looking statements, including without limitation, statements regarding the impact of the new pharmaceutical pricing regulation adopted by the Spanish Ministry of Health on Bentley's business in Spain and its future results. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from future results expressed or implied by such statements. Factors that may cause such differences include, but are not limited to risks associated with changes in government regulations which affect pricing of Bentley's pharmaceutical products, competition from other manufacturers of generic and proprietary pharmaceuticals, and other uncertainties detailed in Bentley's most recent Annual Report on Form 10 and its other subsequent periodic reports filed with the Securities and Exchange Commission. Bentley cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and Bentley undertakes no obligation to update or revise the statements, except as may be required by law.